Systemic mesenchymal stem cell therapy for reduction of inflammatory burden in a patient with juvenile-onset rheumatoid arthritis and dialysis-dependent renal failure - PubMed
4 hours ago
- #rheumatoid arthritis
- #mesenchymal stem cells
- #chronic kidney disease
- The article discusses a case of systemic mesenchymal stem cell (MSC) therapy in a 56-year-old woman with juvenile-onset rheumatoid arthritis and dialysis-dependent chronic kidney disease.
- The patient received three consecutive systemic administrations of MSCs, leading to reduced inflammatory markers such as C-reactive protein, interleukin-6, and tumor necrosis factor-α.
- Improvements were observed in hemoglobin levels, renal function markers, and pain assessment scores, along with subjective pain relief and enhanced overall well-being.
- The report suggests that MSC therapy may offer an immunomodulatory approach for managing chronic inflammation in patients with overlapping autoimmune and uremia-associated conditions, though further controlled studies are needed.